The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer
Most patients with metastatic KRAS G12C-mutated NSCLC are excluded from trials. There is substantial potential to refine trial entry criteria to better balance generalizability, safety, speed, and success.
Authors
- Benjamin Herzberg (ORCID: https://orcid.org/0000-0002-3253-3106)
- Prashasti Agrawal
- Margaux Wooster (ORCID: https://orcid.org/0000-0003-3957-6093)
- MAHESH M. MANSUKHANI (ORCID: https://orcid.org/0000-0003-2044-0751)
- Michael May (ORCID: https://orcid.org/0000-0002-6187-4655)
- Kathryn C. Arbour (ORCID: https://orcid.org/0000-0001-5951-8427)
- Anjali Saqi (ORCID: https://orcid.org/0000-0003-3133-9886)
- Gregory J. Riely (ORCID: https://orcid.org/0000-0001-5357-4313)
- Jonathan Lee (ORCID: https://orcid.org/0000-0003-2163-8348)
- Benjamin May
- Catherine A. Shu (ORCID: https://orcid.org/0000-0003-0765-7665)
- Stephanie Bogdan
- Xin Ma (ORCID: https://orcid.org/0000-0002-0183-4803)
- Brian S. Henick (ORCID: https://orcid.org/0000-0003-2681-0805)
- Christine Ann Garcia (ORCID: https://orcid.org/0000-0002-0367-7813)
- Dawn L. Hershman (ORCID: https://orcid.org/0000-0001-8807-153X)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Columbia University Irving Medical Center (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1093/jnci/djaf236
- Citations
- 2
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.63
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- American Society of Clinical Oncology
- Regeneron Pharmaceuticals
- Jazz Pharmaceuticals
- Revolution Medicines
- Eisai
- Astellas Pharma
- Genentech